What are Tarsus Pharmaceuticals, Inc.'s total assets?

Tarsus Pharmaceuticals, Inc. (TARS) holds $581.1M in total assets, up 16.1% year over year.

How much debt does Tarsus Pharmaceuticals, Inc. have?

Tarsus Pharmaceuticals, Inc. carries $88.7M in total debt against $349.0M of shareholders' equity, a debt-to-equity ratio of 0.25.

How much cash does Tarsus Pharmaceuticals, Inc. have?

Tarsus Pharmaceuticals, Inc. holds $104.2M in cash and equivalents.

Can Tarsus Pharmaceuticals, Inc. cover its short-term obligations?

Its current ratio is 3.74 — current assets exceed current liabilities.

Where does Tarsus Pharmaceuticals, Inc.'s balance sheet data come from?

Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Tarsus Pharmaceuticals, Inc. TARS Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$104.19M-41.6%	$186.2M+91.2%	$115.29M-34.6%	$99.21M-45.2%	$178.35M-7.9%
Short-term investments	$286.54M+23.4%	$233.63M+18.9%	$289.11M+105%	$284.5M+99.7%	$232.13M+121%
Restricted cash	$0-100%	$560K—	$2.56M—	$2.56M—	$2.56M—
Accounts receivable, net	$100.34M+60.7%	$85.06M+81.9%	$72.62M+149%	$58.33M+97.5%	$62.43M+109%
Inventories	$2.53M-0.2%	$2.53M0.0%	$2.53M0.0%	$2.53M0.0%	$2.53M-37.3%
Work in process	$1.63M+114%	$1.41M+130%	$1M-37.1%	$1.58M+32.4%	$764K+12.9%
Finished goods	$2.94M+51.5%	$2.96M+47.7%	$2.84M+126%	$2.29M+129%	$1.94M+135%
Total current assets	$537.23M+11.7%	$522.78M+46.6%	$501.7M+40.5%	$474.43M+30.8%	$480.77M+41.1%
Property and equipment, net	$17.67M+534%	$11.67M+404%	$5.75M+140%	$3.18M+42.0%	$2.79M+108%
Accumulated depreciation	$2.3M+4.5%	$2.1M+6.2%	$2.63M+47.4%	$2.41M+50.8%	$2.2M+50.4%
Operating lease right-of-use assets	11.4%+0.4%	11.4%+0.4%	11.4%+1.4%	11%0.0%	11%+1.0%
Intangible assets, net	$7.13M-11.9%	$7.37M-11.5%	$7.61M-11.2%	$7.85M+114%	$8.09M+115%
Deferred tax assets	——	$6.88M+44.5%	——	——	——
Other non-current assets	$715K+16.1%	$1.86M+86.3%	$1.18M+32.5%	$1.21M+43.4%	$616K-53.2%
Equity method investments	$3.87M+29.0%	$3.87M+29.0%	$3M0.0%	$3M0.0%	$3M—
Allowance for credit losses	——	$13.64M+102%	——	——	——
Total assets	$581.14M+16.1%	$562.16M+49.1%	$534.56M+42.1%	$494.99M+31.4%	$500.75M+43.4%
Accounts payable	$24.13M-15.0%	$16.39M+74.0%	$40.64M+51.6%	$28.08M+5.3%	$28.38M+48.3%
Accrued expenses	$8.53M-14.1%	$17.78M+12.4%	$13.55M+19.7%	$11.61M+44.3%	$9.93M+66.7%
Operating lease liabilities, current	$0-100%	$0-100%	$80K-87.3%	$317K-47.6%	$384K-34.4%
Income taxes payable	$563K—	$1.81M—	——	——	——
Security deposits	$2M-23.1%	$2.6M0.0%	$2.6M—	$2.6M—	$2.6M—
Total current liabilities	$143.51M+66.3%	$135.7M+68.3%	$117.05M+77.7%	$90.25M+75.0%	$86.31M+103%
Long-term debt	$72.6M+0.9%	$72.44M+0.8%	$72.28M+0.8%	$72.13M+0.8%	$71.98M+140%
Operating lease liabilities, non-current	$16.08M—	$10.6M—	$10.15M+718%	$0-100%	$0-100%
Operating Lease Liabilities (Total)	$16.08M+4,087%	$10.6M+1,643%	$10.23M+446%	$317K-84.6%	$384K-82.5%
Other non-current liabilities	$16.08M—	$10.6M—	$10.15M+718%	——	——
Total liabilities	$232.18M+46.7%	$218.73M+43.5%	$199.48M+43.7%	$162.38M+30.3%	$158.29M+114%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	200M0.0%	200M0.0%	200M0.0%	200M0.0%	200M0.0%
Additional paid-in capital	$782.84M+7.6%	$769.67M+31.7%	$753.04M+31.1%	$738.24M+30.4%	$727.7M+31.0%
Retained earnings	-$433.6M-12.5%	-$426.63M-18.4%	-$418.26M-24.1%	-$405.67M-29.3%	-$385.33M-37.4%
Accumulated other comprehensive income (loss)	-$298K-451%	$381K+113%	$289K-16.5%	$39K+122%	$85K+235%
Total stockholders' equity	$348.95M+1.9%	$343.43M+53.0%	$335.08M+41.1%	$332.61M+31.9%	$342.46M+24.4%
Total liabilities and stockholders' equity	$581.14M+16.1%	$562.16M+49.1%	$534.56M+42.1%	$494.99M+31.4%	$500.75M+43.4%
Available-for-Sale Debt Securities - Amortized Cost	$286.84M+23.6%	$233.25M+18.8%	$288.82M+106%	$284.46M+99.4%	$232.04M+119%
Cash, Cash Equivalents, and Marketable Securities	$286.54M+23.4%	$233.63M+18.9%	$289.11M+105%	$284.5M+99.7%	$232.13M+121%
Finished goods	$2.94M+51.5%	$2.96M+47.7%	$2.84M+126%	$2.29M+129%	$1.94M+135%
Short- term Investments	$286.54M+23.4%	$233.63M+18.9%	$289.11M+105%	$284.5M+99.7%	$232.13M+121%
Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)	$16.86M+876%	$2.05M+58.0%	$1.72M+49.9%	$1.91M+45.3%	$1.73M+17.0%
Other Receivables	$16.86M+876%	$2.05M+58.0%	$1.72M+49.9%	$1.91M+45.3%	$1.73M+17.0%
Deferred Tax Assets and Other Non-Current Assets	$715K+16.1%	$124K-26.6%	$1.18M+32.5%	$1.21M+43.4%	$616K-53.2%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	$961K0.0%	$961K0.0%	$961K0.0%	$961K+140%	$961K+140%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year Five)	——	$2.56M-27.3%	——	——	——
Indefinite-Lived Research and Development Assets	——	$7.96M-63.4%	——	——	——
Intangible Assets Gross (Excluding Goodwill)	$9M0.0%	$9M0.0%	$9M—	$9M—	$9M—
Investments - Amortized Cost Basis	$286.84M+23.6%	$233.25M+18.8%	$288.82M+106%	$284.46M+99.4%	$232.04M+119%
Net Investment in Lease	$9.99M+2,443%	$10.08M+1,726%	$10.23M+468%	$229K-88.4%	$393K-81.6%
Net Operating Loss Carryforwards	——	$176.1M+27.1%	——	——	——
Intangible assets — net	$7.13M-11.9%	$7.37M-11.5%	$7.61M-11.2%	$7.85M+114%	$8.09M+115%
Other intangible assets—net	$7.13M-11.9%	$7.37M-11.5%	$7.61M-11.2%	$7.85M+114%	$8.09M+115%
Investments	$3.87M+29.0%	$3.87M+29.0%	$3M0.0%	$3M0.0%	$3M—
Operating lease right-of-use assets	$9.99M+2,443%	$10.08M+1,726%	$10.23M+468%	$229K-88.4%	$393K-81.6%
Other non-current assets	$715K+16.1%	$1.86M+86.3%	$1.18M+32.5%	$1.21M+43.4%	$616K-53.2%
Property, plant and equipment at cost	$19.97M+301%	$13.76M+221%	$8.38M+101%	$5.59M+45.6%	$4.98M+78.1%
Operating Lease Right-of-Use Assets in Other Assets	$9.99M+2,443%	$10.08M+1,726%	$10.23M+468%	$229K-88.4%	$393K-81.6%
Software and Technology Licenses, Net	$715K+16.1%	$1.86M+86.3%	$1.18M+32.5%	$1.21M+43.4%	$616K-53.2%
Tax Credit Carryforward Valuation Allowance	——	$107.94M+22.6%	——	——	——
Accrued liabilities and other current	$110.85M+45.1%	$101.53M+83.4%	$103.5M+89.8%	$78.64M+80.7%	$76.38M+109%
Accrued Manufacturing Costs	$8.53M-14.1%	$17.78M+12.4%	$13.55M+19.7%	$11.61M+44.3%	$9.93M+66.7%
Commissions and Contract Termination Costs	$70.52M+61.4%	$68.44M+107%	$56.35M+148%	$45.12M+186%	$43.69M+167%
Compensation and benefits	$8.53M-14.1%	$17.78M+12.4%	$13.55M+19.7%	$11.61M+44.3%	$9.93M+66.7%
Other accrued liabilities	$32.5M—	$22.18M+21.1%	——	——	——
Lease Liability Payments - 2020 (Remaining Three Months)	$1.78M+217%	——	$80K-65.7%	$321K-31.4%	$562K-14.8%
Operating Lease Liability Payments - 2024 (Lessee)	$2.7M—	$2.63M—	$2.63M+164%	——	——
Operating Lease Liability Payments - 2025 (Lessee)	$2.87M—	$2.78M—	$2.78M—	——	——
Lease Liability Payments - Due Year Two	$2.7M—	$2.63M—	$2.63M+164%	——	——
Lease Liability Payments - Due Year Three	$2.78M—	$2.7M—	$2.7M+3,158%	——	——
Lease Liability Payments - Due Year Four	$2.87M—	$2.78M—	$2.78M—	——	——
Lease Liability Payments - Remainder of Fiscal Year	$2.63M—	$2.02M+153%	$2.02M+110%	——	——
Operating Lease Liability Payments Due	$28.16M+4,910%	$28.4M+3,450%	$28.49M+1,154%	$321K-87.2%	$562K-79.2%
Operating Lease Liability - Undiscounted Excess Amount	$11.49M+81,943%	$11.96M+39,753%	$12.42M+5,184%	$4K-98.6%	$14K-95.9%
Unamortized Discount and Issuance Costs	$3.52M0.0%	$3.52M0.0%	$3.52M0.0%	$3.52M0.0%	$3.52M+303%
Deferred Tax Liabilities - Leasing Arrangements	——	$4.22M+2,983%	——	——	——
Operating Lease Liability Payments - 2026 (Lessee)	$2.78M—	$2.7M—	$2.7M+3,158%	——	——
Operating Lease Liability Payments - 2027 (Lessee)	$2.78M—	$2.87M—	$2.7M+3,158%	——	——
Operating Lease Liability Payments - 2028 (Lessee)	$2.87M—	$2.78M—	$2.78M—	——	——
Operating Lease Liability Payments - 2029 (Lessee)	——	$2.87M—	——	——	——
Lease Liability Payments - Due After Year Five	——	$15.4M—	——	——	——
Operating Lease Liability Payments - Thereafter (Lessee)	——	$15.4M—	——	——	——
Total debt	$88.68M+22.5%	$83.04M+14.6%	$82.51M+12.1%	$72.45M-1.6%	$72.37M+125%
Total Carrying Value of Debt	$75M0.0%	$75M0.0%	$75M0.0%	$75M0.0%	$75M+150%
Unrecognized Tax Benefits	$4.3M—	$4.3M-9.5%	——	——	——
Unrecognized Tax Benefits - Impacting Effective Tax Rate	——	$0—	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Accumulated Loss	70+268%	7-30.0%	16+700%	51+59.4%	19-26.9%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	43M+2.4%	42.6M+11.0%	42.4M+11.1%	42.2M+11.0%	42M+11.2%
Common Stock Shares Outstanding	$248.78M+55.4%	$312.65M+73.0%	$197.11M+150%	$105.74M+80.7%	$160.11M+66.3%
Convertible Preferred Stock Authorized Shares	10M0.0%	10M0.0%	10M0.0%	10M0.0%	10M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$6K0.0%	$6K0.0%	$6K0.0%	$6K0.0%	$6K0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Number of Exercisable Options	4.1M+14.6%	——	3.7M+13.6%	3.7M+18.9%	3.6M+20.2%
Number of Vested and Expected to Vest Options	——	$248.05M+88.8%	——	——	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment Award Options Outstanding - Number	5.6M+5.2%	5.2M+4.5%	5.2M+3.8%	5.3M+3.9%	5.4M+2.6%
Shares Reserved for Future Issuance Under Stock Plans	19.5M+6.0%	17.9M+3.8%	18M+5.4%	18.2M+5.8%	18.4M+5.3%
Unrealized Gains on Investments	$91K-19.5%	$389K+88.8%	$333K-4.3%	$108K+10,700%	$113K+2,725%
Unrealized Losses on Investments (Before Tax)	$389K+1,289%	$9K-67.9%	$44K+2,100%	$70K-60.2%	$28K-97.5%
Warrants and Rights Outstanding	312.5K0.0%	312.5K0.0%	312.5K—	312.5K—	312.5K—
Weighted Average Exercise Price of Outstanding Options	$26.37+22.8%	$22.11+14.6%	$21.88+15.5%	$21.61+14.6%	$21.47+14.0%
Weighted Average Exercise Price of Vested and Expected to Vest Options	——	$17.76+10.0%	——	——	——
Cumulative Cost Basis	$286.84M+23.6%	$233.25M+18.8%	$288.82M+106%	$284.46M+99.4%	$232.04M+119%
Accrued royalty payable	$7.27M+85.6%	$9.1M+174%	$6.43M+167%	$5.13M—	$3.92M—
Accumulated amortization, debt issuance costs	$1.12M+121%	$961K+161%	$804K+248%	$652K+546%	$507K+74.2%
Area of Real Estate Property	$98.81K—	$98.81K+65.7%	$98.81K—	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$389K+1,289%	$9K-67.9%	$44K+2,100%	$70K-60.2%	$28K-97.5%
Gross Unrealized Gains	$91K-19.5%	$389K+88.8%	$333K-4.3%	$108K+10,700%	$113K+2,725%
Total	$286.84M+23.6%	$233.25M+18.8%	$288.82M+106%	$284.46M+99.4%	$232.04M+119%
Available for sale investments	$286.54M+23.4%	$233.63M+18.9%	$289.11M+105%	$284.5M+99.7%	$232.13M+121%
Unrealized gains	——	$1K0.0%	——	——	——
Pre-funded warrants reserved for future issuance (in shares)	312.5K0.0%	312.5K0.0%	312.5K0.0%	312.5K0.0%	312.5K0.0%
Performance stock units issued and outstanding (unvested) under the 2020 Plan (in shares)	721.3K+4.1%	724.8K—	714.8K—	692.6K—	692.6K—
Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant	7.9M+9.3%	7M-2.2%	7.1M-2.7%	7.2M-2.2%	7.3M-2.2%
Common Stock, Capital Shares Reserved for Future Issuance, Employee Stock Purchase Plan	3.2M+12.5%	2.8M+1.1%	2.8M+1.4%	2.8M+1.4%	2.9M+0.2%
Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Restricted Stock Units Available For Future Grant	1.7M-12.2%	1.8M-8.3%	1.7M-7.4%	1.8M-4.6%	1.9M-2.5%
Performance stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan (in shares)	——	724.8K—	——	——	——
Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Options Issued And Outstanding	5.6M+5.2%	5.2M+4.5%	5.2M+3.8%	5.3M+3.9%	5.4M+2.6%
Common stock, capital shares reserved for future issuance	$19.53M+6.0%	$17.87M+3.8%	$17.97M+5.4%	$18.21M+5.8%	$18.42M+5.3%
Common stock votes	10.0%	10.0%	10.0%	10.0%	10.0%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$200M0.0%	$200M0.0%	$200M0.0%	$200M0.0%	$200M0.0%
Common stock, shares issued (in shares)	$43.02M+2.4%	$42.55M+11.0%	$42.45M+11.1%	$42.21M+11.0%	$42M+11.2%
Common Stock, Shares, Outstanding	$43.02M+2.4%	$42.55M+11.0%	$42.45M+11.1%	$42.21M+11.0%	$42M+11.2%
Long-term debt, gross	$75M0.0%	$75M0.0%	$75M0.0%	$75M0.0%	$75M+150%
Debt Issuance Costs, Line of Credit Arrangements, Net	$3.52M0.0%	$3.52M0.0%	$3.52M0.0%	$3.52M0.0%	$3.52M+303%
Number of securities with contractual maturity between one and three years	29+263%	20+150%	29+867%	6+200%	8+100%
Deferred Tax Assets, Charitable Contribution Carryforwards	——	$27.69M+213%	——	——	——
Deferred Tax Assets, Goodwill and Intangible Assets	——	$3.58M-2.3%	——	——	——
Deferred Tax Assets, Gross	——	$112.67M+27.5%	——	——	——
Deferred Tax Assets, Net	——	$0—	——	——	——
Deferred Tax Assets, Net of Valuation Allowance	——	$4.74M+1,238%	——	——	——
Operating lease liability	——	$4.36M+2,788%	——	——	——
Deferred Tax Assets, Operating Loss Carryforwards	——	$41.46M+23.1%	——	——	——
R&D credit carryforward	——	$6.99M-19.2%	——	——	——
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost	——	$6.88M+44.5%	——	——	——
Temporary differences related to Texas Margin Tax	——	$13.64M+102%	——	——	——
Deferred Tax Assets, Valuation Allowance	——	$107.94M+22.6%	——	——	——
Prepaid expenses	——	$328K—	——	——	——
Deferred Tax Liabilities, Property, Plant and Equipment	——	$186K-14.3%	——	——	——
Thereafter	$2.56M-27.3%	——	$3.52M-21.4%	$3.52M+88.6%	$3.52M+88.6%
Finite-Lived Intangible Assets, Accumulated Amortization	$1.87M+105%	$1.63M+142%	$1.39M—	$1.15M—	$914K—
2028	$961K0.0%	$961K0.0%	$961K0.0%	$961K+140%	$961K+140%
2030	$961K0.0%	$961K0.0%	$961K0.0%	$961K+140%	$961K+140%
2031	——	$961K0.0%	——	——	——
Remainder of 2026	$721K0.0%	——	$240K0.0%	$480K+140%	$721K+140%
2027	$961K0.0%	$961K0.0%	$961K0.0%	$961K+140%	$961K+140%
2029	$961K0.0%	$961K0.0%	$961K0.0%	$961K+140%	$961K+140%
Finite Lived Intangible Assets Amortization Expense After Year Five	——	$2.56M-27.3%	——	——	——
Incentive From Lessor	——	——	——	——	——
Indefinite- lived intangible impairment	$9M0.0%	$9M0.0%	$9M—	$9M—	$9M—
Inventory, Current And Noncurrent, Net	$7.1M+35.6%	$6.9M+34.0%	$6.37M+18.4%	$6.41M+35.5%	$5.24M—
Raw materials	$2.53M-0.2%	$2.53M0.0%	$2.53M0.0%	$2.53M0.0%	$2.53M—
Annual increase in rent (as a percent)	——	——	——	——	——
Lessee Operating Lease Liability Payments Due	$28.16M+4,910%	$28.4M+3,450%	$28.49M+1,154%	$321K-87.2%	$562K-79.2%
Lessee, Operating Lease, Liability, Tenant Improvement Allowance	$592K+261%	$5.84M+3,507%	$5.84M+3,463%	——	$164K0.0%
Thereafter	$15.4M—	——	$18.28M—	$0—	$0—
Lessee Operating Lease Liability Undiscounted Excess Amount	$11.49M+81,943%	$11.96M+39,753%	$12.42M+5,184%	$4K-98.6%	$14K-95.9%
Number of leases	2-66.7%	2-66.7%	2-66.7%	60.0%	60.0%
Tenant improvement allowance	——	——	——	——	——
Number of employment arrangements with executive officers	70.0%	70.0%	7+16.7%	7+16.7%	7+16.7%
Operating Lease Weighted Average Discount Rate Percent	$0.11+3.6%	$0.11+3.6%	$0.11+14.0%	$0.110.0%	$0.11+10.0%
Operating Loss Carryforwards	——	$176.1M+27.1%	——	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Prepaid expenses	$26.72M+345%	$13.47M-8.0%	$21.7M+209%	$29.17M+388%	$6M-11.8%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	——	$17.76+10.0%	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	$4.1M+14.6%	——	$3.74M+13.6%	$3.72M+18.9%	$3.57M+20.2%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$5.63M+5.2%	$5.23M+4.5%	$5.25M+3.8%	$5.32M+3.9%	$5.35M+2.6%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	——	$3.87M+15.5%	——	——	——
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	——	$248.05M+88.8%	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$26.37+22.8%	$22.11+14.6%	$21.88+15.5%	$21.61+14.6%	$21.47+14.0%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$248.78M+55.4%	$312.65M+73.0%	$197.11M+150%	$105.74M+80.7%	$160.11M+66.3%
Unvested	$37.56M-0.6%	$64.59M+31.0%	$40.3M+141%	$17.16M+33.6%	$37.8M+24.2%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$18.59+8.5%	——	$17.52+10.1%	$17.43+12.5%	$17.14+10.5%
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares	1.5M-13.8%	1.4M-17.9%	1.5M-14.5%	1.6M-19.5%	1.8M-20.7%
Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price	$47.13+56.3%	$34.46+34.4%	$32.71+32.9%	$31.31+29.7%	$30.16+29.9%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	$211.21M+72.7%	——	$156.81M+153%	$88.58M+93.9%	$122.31M+85.8%
Unrecognized tax benefits	$4.3M—	$4.3M-9.5%	——	——	——
Amount that if recognized, would affect the effective tax rate or regulatory liability	——	$0—	——	——	——
Remainder of Fiscal Year 2024	$1.78M+217%	——	$80K-65.7%	$321K-31.4%	$562K-14.8%
Remainder of Fiscal Year 2025	$721K0.0%	——	$240K0.0%	$480K+140%	$721K+140%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Tarsus Pharmaceuticals, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Tarsus Pharmaceuticals, Inc.'s total assets?: Tarsus Pharmaceuticals, Inc. (TARS) holds $581.1M in total assets, up 16.1% year over year.
How much debt does Tarsus Pharmaceuticals, Inc. have?: Tarsus Pharmaceuticals, Inc. carries $88.7M in total debt against $349.0M of shareholders' equity, a debt-to-equity ratio of 0.25.
How much cash does Tarsus Pharmaceuticals, Inc. have?: Tarsus Pharmaceuticals, Inc. holds $104.2M in cash and equivalents.
Can Tarsus Pharmaceuticals, Inc. cover its short-term obligations?: Its current ratio is 3.74 — current assets exceed current liabilities.
Where does Tarsus Pharmaceuticals, Inc.'s balance sheet data come from?: Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.